Infliximab for Managing Steroid-Refractory Acute Graft-versus-Host Disease Joseph Pidala, Jongphil Kim, Teresa Field, Ali McBride, Mohamed Kharfan-Dabaja, Janelle Perkins, Hugo Fernandez, Lia Perez, Ernesto Ayala, Claudio Anasetti Biology of Blood and Marrow Transplantation Volume 15, Issue 9, Pages 1116-1121 (September 2009) DOI: 10.1016/j.bbmt.2009.05.019 Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Overall aGVHD grade in patients on weekly evaluation after initiation of infliximab therapy. Biology of Blood and Marrow Transplantation 2009 15, 1116-1121DOI: (10.1016/j.bbmt.2009.05.019) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 Overall survival. Biology of Blood and Marrow Transplantation 2009 15, 1116-1121DOI: (10.1016/j.bbmt.2009.05.019) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 3 Overall survival, those achieving a CR of aGVHD with infliximab versus those not achieving a CR. Biology of Blood and Marrow Transplantation 2009 15, 1116-1121DOI: (10.1016/j.bbmt.2009.05.019) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions